Maxigen Biotech Inc.
Maxigen Biotech Inc., a leading player in the biotechnology sector, is headquartered in Taiwan (TW) and operates extensively across Asia and beyond. Founded in 2000, the company has established itself as a pioneer in the development of innovative biopharmaceuticals and advanced diagnostic solutions. Specialising in the production of recombinant proteins, monoclonal antibodies, and cell culture products, Maxigen Biotech stands out for its commitment to quality and cutting-edge technology. The company’s unique offerings cater to various industries, including pharmaceuticals, diagnostics, and research. With a strong market position, Maxigen Biotech has achieved significant milestones, including collaborations with major research institutions and a robust portfolio of patented technologies. This dedication to innovation and excellence has solidified its reputation as a trusted partner in the global biotech landscape.
DitchCarbon Score
How does Maxigen Biotech Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Maxigen Biotech Inc.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Maxigen Biotech Inc.'s reported carbon emissions
Maxigen Biotech Inc., headquartered in Taiwan (TW), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no documented Scope 1, 2, or 3 emissions to analyse. Furthermore, the company has not established any formal reduction targets or commitments, such as those aligned with the Science Based Targets initiative (SBTi). This lack of data suggests that Maxigen Biotech Inc. may still be in the early stages of developing its climate strategy or reporting framework. As the biotechnology industry increasingly prioritises sustainability, it is essential for companies like Maxigen Biotech Inc. to consider implementing measurable climate commitments and reduction initiatives to align with global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Maxigen Biotech Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
